Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-06-13
2006-06-13
Helms, Larry R. (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023530, C530S387300, C530S388850, C435S069100, C435S069600, C435S325000, C435S252300
Reexamination Certificate
active
07060808
ABSTRACT:
A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.
REFERENCES:
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 5225539 (1993-07-01), Winter
patent: 5859205 (1999-01-01), Adair et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6639055 (2003-10-01), Carter et al.
patent: 0 460 167 (1995-10-01), None
patent: WO 91/0996 (1991-07-01), None
patent: WO A 92/22653 (1992-12-01), None
Vinkemeier, J. Cell Science 106:319, 1993.
Paul, Fundamental Immunology 242, Chapter 8, p 242, 1993.
Panka et al., Proc. Natl. Acad. Sci. 85:3080-3084, 1988.
Amit et al., Science 233:747-53, 1986.
Morrison et al., Ann. Rev. Immnol. 2:239-56, 1984.
Lyons et al., Protein engineering 3:703-708, 1990.
Walter., Proc. Natl. Acad. Sci. USA 77:5197:5200, 1980.
Axelsson, Acta Chemica Scandinavica B 39:69-77, 1985.
Paulus et al., Behring inst Mitt No 78:118-132, 1985.
Riechmann et al., Nature 332:323-327, 1988.
Rudikoff et al., Proc. Natl. Acad. Sci. USA 79:1979-83, 1982.
Kettleborough, et al., PCT Application WO95/25167 Sep. 21, 1995.
Hurwitz, et al., Int. J. Cancer 37, 739-745 (1986).
Scher, et al. Clinical Cancer Research 1, 545-550 (May 1995).
Baselga, et al., Journal of the National Cancer Institute 85, 1327-1333 (1993).
Beerli, et al., Biochemical and Biophysical Research Communications 204, 666-672 (1994).
Divgi, et al., Journal of The National Cancer Institute 83, 97-104 (1991).
Naramura, et al., Cancer Immunology Immunotherapy 37, 343-349 (1993).
Naramura, et al., Immunology Letters 39, 91-99 (1994).
Schechter, et al., Int. J. Cancer 48, 167-172 (1991).
Wels, et al., International Journal of Cancer 60, 137-144 (1995).
J. Baselga et al., “Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies”, Journal of the National Cancer Institute, vol. 85, No. 16, pp. 1327-1333, Aug. 18, 1993.
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy” Proc. Natl. Acad. Sci. USA, vol. 89, pp. 4285-4289, May 1992.
C. Chothia et al., “Conformations of immunoglobulin hypervariable regions” Nature, vol. 342, pp. 877-883, Dec. 1989.
Graziani et al., “Regulation of Protein Kinases Activity by Quercetin in Ehrlich Ascites Tumor Cells” Biochimica et Biophysica Acta, vol. 714, pp. 415-421, 1981.
G. James et al., “Benzidiazepine Peptidimimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells” Science, vol. 260, pp. 1937-1942, Jun. 25, 1993.
K. Sato et al., “Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth” Cancer Research, vol. 53, pp. 851-856, Feb. 15, 1993.
R. Taub et al., “A Monoclonal Antibody against the Platelet Fibrinogen Receptor Contains a Sequence That Mimics a Receptor Recognition Domain in Fibrinogen” Journal of Biological Chemistry, vol. 264, No. 1, Jan. 5, 1989.
Yang et al., “Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice” Proc. Natl. Acad. Sci. vol. 85, pp. 1189-1193, Feb. 1988.
Giorgio Nicholas A.
Goldstein Neil I.
Jones Steven Tarran
Saldanha Jose William
ImClone Systems Incorporated
Kenyon & Kenyon
Tungaturthi Parithosh K.
LandOfFree
Humanized anti-EGF receptor monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-EGF receptor monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-EGF receptor monoclonal antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3680639